Left ventricular hypertrophyLeft ventricular non-hypertrophy
Left ventricular hypertrophy: Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
Left ventricular non-hypertrophy: Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
Study summary
The investigators want to explore the relationship between different configurations of hypertension and the incidence of cardiovascular events by the guidelines reference range and EMINCA recommended reference range. Then the investigators want to enroll twenty research centers and 2200 hypertensions were planned to be collected and followed up in the 12th, 24th, 36th and 48th months after being enrolled in this study. Physical examination, ECG examination, laboratory examination, echocardiography and carotid ultrasound should be taken when baseline and follow-up. Echocardiographic measurement parameters were analyzed and the relationship between the echocardiographic measurement parameters and cardiovascular events and prognosis of hypertension.
Eligibility
Sex
ALL
Min age
30 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Age 30-75 years old;
2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg;
3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5).
4. All patients agreed to participate in the experiment and signed the informed consent form.
Exclusion Criteria:
1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases;
2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery;
3. Abnormal liver function; abnormal renal function and diabetes;
4. Pregnant or breastfeeding women;
5. Expected survival time due to non-cardiovascular disease\<4 years;
6. Patients with poor echocardiographic image quality.
Primary outcome measure(s)
Emerging atrial fibrillation — Through study completion, on average once a year. The differences in the incidence of atrial fibrillation between the two groups
Emerging unstable angina, myocardial infarction, heart failure, coronary revascularization, cardiovascular death — Through study completion, on average once a year. The differences in the incidence of unstable angina, myocardial infarction, heart failure, coronary revascularization, cardiovascular death between the two groups
Emerging transient ischemic attack (TIA) or stroke — Through study completion, on average once a year. The differences in the incidence of transient ischemic attack (TIA) or stroke between the two groups
Trial sites (1)
Facility
City
Region
Status
Qilu Hospital of Shandong University
Jinan
Shandong
Recruiting
More Qilu Hospital of Shandong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.